Latest Ratios: P/E Ratio 158.8x · EV/EBITDA N/A · ROE 2.6%. (2023–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Market Cap | $165M | $259M | $97M | — |
| Enterprise Value | $167M | $261M | $97M | — |
| P/E Ratio → | 158.82 | 376.53 | 38.21 | — |
| P/S Ratio | — | — | — | — |
| P/B Ratio | 13.59 | 32.22 | 1.34 | — |
| P/FCF | — | — | — | — |
| P/OCF | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| EV / Revenue | — | — | — | — |
| EV / EBITDA | — | — | — | — |
| EV / EBIT | — | — | — | — |
| EV / FCF | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Gross Margin | — | — | — | — |
| Operating Margin | — | — | — | — |
| Net Profit Margin | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ROE | 2.6% | 2.6% | 3.6% | 0.2% |
| ROA | 2.5% | 2.5% | 3.5% | 0.2% |
| ROIC | -1.5% | -1.5% | -1.1% | — |
| ROCE | -2.0% | -2.0% | -1.5% | -0.0% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Debt / Equity | 0.25 | 0.25 | 0.00 | — |
| Debt / EBITDA | — | — | — | — |
| Net Debt / Equity | — | 0.25 | 0.00 | -0.01 |
| Net Debt / EBITDA | — | — | — | -3.39 |
| Debt / FCF | — | — | — | — |
| Interest Coverage | — | — | — | — |
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Current Ratio | 0.00 | 0.00 | 0.04 | 23.38 |
| Quick Ratio | 0.00 | 0.00 | 0.04 | 23.38 |
| Cash Ratio | 0.00 | 0.00 | 0.03 | 23.38 |
| Asset Turnover | — | — | — | — |
| Inventory Turnover | — | — | — | — |
| Days Sales Outstanding | — | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Dividend Yield | — | — | — | — |
| Payout Ratio | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Earnings Yield | 0.6% | 0.3% | 2.6% | — |
| FCF Yield | — | — | — | — |
| Buyback Yield | 39.5% | 25.2% | 0.0% | — |
| Total Shareholder Yield | 39.5% | 25.2% | 0.0% | — |
| Shares Outstanding | — | $4M | $9M | $9M |
Immediate going concern liquidity
According to recent SEC filings, AFJK trades at a P/B of 13.49, a valuation that appears fundamentally detached from the company's near-zero cash position and lack of operational revenue, suggesting the market may be pricing in speculative merger potential rather than current tangible book value.
The elevated P/B ratio relative to the company's historical range and peer group suggests that investors are assigning a significant premium to the shell's listing status. This valuation implies an expectation of a transformative business combination that is not currently supported by the entity's deteriorating financial health.
Based on the company's reported figures, the ROE has remained stagnant at approximately 0.6% as of 2026Q1, reflecting a lack of meaningful income generation that renders traditional DuPont decomposition metrics largely irrelevant for this pre-revenue shell entity.
The minimal profitability metrics indicate that the firm is not currently functioning as a productive financial institution. Investors should monitor whether the management team can pivot from this stagnant state toward a viable acquisition target, as current returns are insufficient to cover basic administrative overhead.
As reported in financial statements, the equity-to-total-assets ratio has fluctuated significantly, settling at 0.66 in 2026Q1, which indicates a shrinking capital buffer that may limit the entity's ability to sustain its public listing or pursue future acquisition opportunities.
The decline in the equity base suggests that the firm is consuming its capital to fund ongoing operational costs. This trend warrants further investigation into the sustainability of the current capital structure, particularly given the absence of revenue-generating activities.
Data from the most recent quarterly reports indicates that the P/B ratio is the most commonly misapplied metric for AFJK, as it obscures the reality that the company's book value is largely composed of illiquid assets rather than deployable capital for a business combination.
Relying on P/B for a shell company like AFJK is misleading because it fails to account for the 'going concern' risk associated with the nominal cash balance. Analysts should instead focus on the cash-to-burn rate and the proximity to the entity's charter-mandated expiration date to assess true value.
Includes 30+ ratios · 3 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying AFJK stock.
Aimei Health Technology Co., Ltd's current P/E ratio is 158.8x. The historical average is 38.2x. This places it at the 100th percentile of its historical range.
Aimei Health Technology Co., Ltd's return on equity (ROE) is 2.6%. The historical average is 2.2%.
Based on historical data, Aimei Health Technology Co., Ltd is trading at a P/E of 158.8x. This is at the 100th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.